Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

© 2019 Wolters Kluwer Health, Inc. All rights reserved. Background:Bictegravir, coformulated with emtricitabine/tenofovir alafenamide as a fixed-dose combination (B/F/TAF), is recommended for treatment of HIV-1-infection. Multiple studies of B/F/TAF in treatment-naive and virologically suppressed co...

全面介紹

Saved in:
書目詳細資料
Main Authors: Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L. Stephens, Edwin Dejesus, Hui Wang, Rima K. Acosta, Huyen Cao, Erin Quirk, Hal Martin, Tariro Makadzange
格式: 雜誌
出版: 2020
主題:
Medicine
在線閱讀:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073178758&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/67951
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

因特網

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073178758&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/67951

相似書籍